Ipamorelin 5mg

The defining research characteristic of ipamorelin is the selectivity of its GH-releasing action. In the original rat and swine studies it released GH with potency similar to GHRP-6, but did not raise ACTH or cortisol beyond the levels seen with GHRH, unlike GHRP-6 and GHRP-2 (Raun et al., 1998). This selectivity refers to GH release relative to other pituitary hormones, not to exclusive receptor binding.

The GHS-R1a activation mechanism follows the pathway: GHS-R1a binding leads to Gq protein stimulation, which activates phospholipase C (PLC), generating IP3 and DAG, which elevates intracellular calcium, ultimately triggering pulsatile GH secretion from somatotroph cells. This ghrelin receptor pathway is distinct from the GHRH receptor pathway targeted by CJC-1295 Without DAC 10mg.

Evidence status: besides the original animal studies, ipamorelin has been tested in humans. In a randomised, placebo-controlled phase 2 trial in 114 patients after bowel resection, intravenous ipamorelin was well tolerated, but the difference in time to tolerating solid food was not statistically significant (Beck et al., Int J Colorectal Dis, 2014). It has not been approved as a medicine. These data do not describe or verify the research material supplied here. No certificate is published yet for the 5mg format; the Ipamorelin 10mg report does not cover 5mg vials.

The 5mg format of ipamorelin is appropriate for pilot studies, method validation, and first-time GHRP research. For established programmes requiring full dose-response gradients, multi-arm designs, and extended single-batch longitudinal studies, Ipamorelin 10mg provides the advanced format. For downstream growth factor research alongside ipamorelin protocols, IGF-1 LR3 1mg targets the IGF-1 receptor axis, providing a mechanistically distinct complement. For mechanism background and published references, see What Is Ipamorelin?.